Skip to content
Screener

Celcuity CELC Professional service fees

Professional service fees at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.55B+150%
Enterprise value$4.54B+142%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.

The source filing: Celcuity’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 5:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001493152-26-023180
Line itemMarch 31, 2026 / As ofDecember 31, 2025 / As of
Employee compensation and benefits$5,441$8,338
License milestone5,000
Research and development costs3,0111,218
Interest1,9983,379
Consulting and professional fees2,2712,335
Other1,252595
Total$13,973$20,865
Other accrued liabilities, current$13,973$20,865

Item 1. Financial Statements (unaudited) ITEM

FAQ

What is Celcuity's professional service fees?
Celcuity (CELC) reported professional service fees of $2.27M in Q1 2026.

Ask your AI about Celcuity's professional service fees.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude